Stocktoria
Ensysce Biosciences, Inc. ENSC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-12-01
Ensysce Biosciences, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -202.1% | -129.2% | -480.5% | -959.9% | -562.7% |
| FCF margin | -156.5% | — | — | — | — |
| Current ratio | 1.59 | 2.42 | 0.69 | 0.56 | 0.95 |
| Revenue growth | -2.8% | 133.6% | -11.6% | -28.5% | -10.2% |
Source: SEC EDGAR filings · CIK 0001716947 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.